Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513125 | 0.86 | AOC3 (0.37) | AOC3HCAR3POLBALDH1A1MEN1 | |
| SCHEMBL3782597 | 0.85 | AOC3 (0.36) | AOC3HCAR3POLBALDH1A1MEN1 | |
| SCHEMBL480491 | 0.85 | AOC3 (0.39) | AOC3HCAR3POLBALDH1A1MEN1 | |
| SCHEMBL29034266 | 0.80 | GBA1 (0.46) | HCAR3ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2637433 | 0.79 | CES2 (0.38) | AOC3HCAR3ALDH1A1MEN1KMT2A | |
| SCHEMBL17162168 | 0.78 | POLB (0.33) | POLB | |
| SCHEMBL2024547 | 0.78 | POLB (0.42) | POLBALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4923675 | 0.78 | RAB9A (0.40) | HCAR3ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3514121 | 0.77 | HCAR3 (0.35) | HCAR3POLBALDH1A1MEN1KMT2A | |
| SCHEMBL15575141 | 0.76 | HCAR3 (0.33) | AOC3HCAR3POLBKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | disclosed |
| US-8916580-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2014-12-23 | — | — | US | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-09-26 | — | — | US | disclosed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1740569-B1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-20 | — | — | EP | disclosed |
| EP-1864979-A1 | Imidazole-derivatives as TAFAIa-inhibitors | Sanofi-Aventis Deutschland GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1740569-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005105781-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-10 | — | — | WO | disclosed |
| WO-2003013526-A1 | ANTICOAGULANT COMPOUNDS | MERCK & CO. INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | AOC3 1695/4885HCAR3 611/4885POLB 4607/4885 |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | NR1H2, NR1H3, NR1I2 | AOC3 2447/4885HCAR3 383/4885POLB 3373/4885 |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | AOC3 1961/4885HCAR3 4265/4885POLB 1365/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | AOC3 1695/4885HCAR3 611/4885POLB 4607/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | AOC3 2351/4885HCAR3 316/4885POLB 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.